Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipher Receives “Approvable” Letter For CIP-Isotretinoin

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA letter appears to resolve questions about the appropriate pathway for the acne medication.

You may also be interested in...



Cipher To Appeal “Approvable” Letter for CIP-Isotretinoin

Toronto firm maintains agency’s request for additional clinical data has already been addressed in existing NDA package.

Cipher To Appeal “Approvable” Letter for CIP-Isotretinoin

Toronto firm maintains agency’s request for additional clinical data has already been addressed in existing NDA package.

Cipher CIP-Tramadol ER Will Not Need Alcohol Interaction Study

Cipher no longer needs to complete a Phase I trial to investigate a potential interaction between the once-daily sustained-release pain medication CIP-tramadol ER and high levels of alcohol, the firm said June 15

Related Content

Topics

UsernamePublicRestriction

Register

PS064188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel